Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 0.45 |
| ▸ | FAAH | O00519 | 10/20 | 0.45 |
| ▸ | AADAC | P22760 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7657873 | 0.87 | EPHX2 (0.54) | EPHX2FAAHAADACFPR2PROKR1 | |
| SCHEMBL2296998 | 0.83 | MGLL (0.44) | EPHX2 | |
| SCHEMBL18960369 | 0.83 | EPHX2 (0.48) | EPHX2FAAHAADACFPR2PROKR1 | |
| SCHEMBL2089029 | 0.82 | TEAD1 (0.49) | EPHX2FPR2PROKR1MMP13MMP2 | |
| SCHEMBL2302138 | 0.80 | SCN9A (0.41) | EPHX2 | |
| SCHEMBL2300932 | 0.80 | SCN9A (0.42) | EPHX2FPR2PROKR1 | |
| SCHEMBL3126722 | 0.79 | EPHX2 (0.46) | EPHX2FAAHFPR2PROKR1 | |
| SCHEMBL2299165 | 0.79 | CARM1 (0.56) | — | |
| SCHEMBL2096027 | 0.79 | PDE2A (0.37) | NISCH | |
| SCHEMBL2301156 | 0.79 | SCN9A (0.42) | EPHX2FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | EPHX2 3535/4885FAAH 170/4885AADAC 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.